Chapter 22 — Key Takeaways

Neuropeptide Y, Substance P, and the Peptides That Regulate Stress, Pain, and Appetite in the Brain

The one-sentence version

Four neuropeptide systems with equally strong mechanistic cases produced four completely different clinical outcomes, and what separated them was not the quality of the mechanism but whether the program had a well-defined indication, direct human evidence that the peptide mattered there, and a target it could actually reach.

The structural ideas

Neuropeptides are the slow layer. They are released from the same neurons as classical fast transmitters, but from dense-core vesicles farther from the active zone, requiring sustained higher-frequency firing rather than a single spike. They act on GPCRs over seconds to minutes.

Firing rate is not a volume knob. Past a certain intensity, a neuron begins sending a second, chemically distinct message. A circuit under mild stimulation and the same circuit under intense stimulation are not the same signal at different amplitudes.

Neuromodulator is a functional word, not a size word. A neuropeptide typically does not excite or inhibit a cell outright; it changes how the cell responds to everything else arriving at it. This is why neuropeptide drugs alter the character of a response rather than switching it on or off — which is both their selectivity advantage and the reason their effects are hard to demonstrate in trials.

No reuptake, no recycling. Neuropeptides are degraded extracellularly and must be resynthesized in the cell body and shipped down the axon. Stores are exhaustible over hours, which makes peptide signaling a low-frequency, high-significance channel by construction.

The four stories

Neuropeptide Y — the most potent appetite stimulator, and no drug

• 36 residues; among the most abundant neuropeptides in the mammalian brain.
• Centrally administered in animals it produces the most potent stimulation of food intake of any known substance — voracious eating in an animal that has just been fed.
• Co-released with AgRP from the arcuate neurons that leptin inhibits (Chapter 13). NPY is not a side effect of the hunger circuit; it is a large part of the message.
• Explains, at the peptide level, the persistent hunger that follows substantial weight loss.
• Y receptor antagonists were taken into human obesity trials and did not produce clinically meaningful weight loss. Explanations offered: redundancy, an acute-versus-chronic gap, species difference. None of them says the mechanism was wrong.
• The human stress-resilience literature is observational: circulating NPY has been associated with better performance in high-stress populations. Four causal readings fit that observation equally well, and no human intervention trial exists.

Substance P — the field's best cautionary tale

• 11 residues, RPKPQQFFGLM-NH2; founding tachykinin; acts principally at NK1.
• Preclinical case as strong as neuroscience produces: precise localization in C fibers and the superficial dorsal horn, release requiring high-frequency firing, slow depolarization of second-order neurons, converging genetic and lesion evidence, plus limbic expression suggesting a mood indication.
• NK1 antagonists failed comprehensively as analgesics and as antidepressants — repeatedly, across compounds and companies, with an early positive depression trial that did not replicate.
• Human PET confirmed the compounds occupied central NK1 receptors at the doses tested. Not underdosed; not off target.
• What survived: NK1 antagonists (aprepitant and relatives) are approved and effective for chemotherapy-induced nausea and vomiting — the indication nobody set out to develop, and the one whose target site (the area postrema) sits outside the blood-brain barrier.

Orexin — the cleanest deficiency, and the asymmetry it exposes

• Two peptides from one precursor, made in the lateral hypothalamus; two names because two groups found them independently in 1998; two receptors, OX1R and OX2R; they stabilize wakefulness.
• Loss of orexin neurons causes narcolepsy type 1 — canine receptor mutation, orexin-null mice, and low or undetectable CSF orexin-A in humans. One of the cleanest neuropeptide-deficiency-to-disease links known.
• Orexin receptor antagonists became approved insomnia drugs (suvorexant and successors) — a genuinely new hypnotic class that removes a wake-promoting signal rather than broadly enhancing inhibition.
• Replacement remains unsolved. The peptide does not enter the brain. The field is pursuing small-molecule agonists instead; one early program was halted for liver toxicity.
• The asymmetry is the lesson: antagonism was solvable with a small molecule; replacement requires either delivering a peptide into the brain or solving the harder chemistry of small-molecule agonism.

CGRP — the success

• 37 residues, from the calcitonin gene by alternative splicing; potent vasodilator; released from trigeminal sensory neurons.
• Complete human causal chain: CGRP rises during attacks; infusing CGRP triggers migraine-like attacks in migraineurs; blocking CGRP or its receptor prevents attacks in randomized trials.
• Approved therapies: anti-CGRP and anti-receptor monoclonal antibodies, and small-molecule gepants. The first genuinely migraine-specific preventive class in history.
• The peptide is the target, not the drug. Every -mab is an antibody (~150,000 Da); the gepants are small molecules. Neither is a peptide.

The blood-brain barrier

• Tight junctions between capillary endothelial cells, plus efflux transporters, plus degrading enzymes. The default for a peptide is: does not enter.
• A neuropeptide with a perfect mechanism and no route in is a research tool, not a drug candidate.
• Three exceptions make the rest legible: circumventricular organs (area postrema, Chapter 7); saturable transport systems for a few specific peptides (insulin, leptin — a property of those molecules, not of peptides generally); and targeting the receptor from outside the brain, which is what CGRP therapies do.
• For any CNS peptide claim, "how does it get there?" settles most arguments before they start.

The comparison that is the chapter's payoff

Substance P and CGRP: both sensory neuropeptides, often in the same neurons, both implicated in pain, both exhaustively characterized. One produced comprehensive failure; the other a major therapeutic class. Mechanism did not distinguish them in advance.

Three things differed:

1. A specific indication with a validated endpoint. Migraine, counted in monthly migraine days — versus "chronic pain" and "major depression," heterogeneous categories with subjective scales and large placebo responses.
2. Direct human evidence that the peptide mattered. A provocation study reproduced the clinical event in the target population. Substance P had no equivalent, and species differences in NK1 pharmacology made its animal behavioral case shakier than it looked.
3. An accessible target. CGRP's relevant signaling is substantially peripheral, so antibodies were usable and the barrier could be routed around.

Mechanism alone is a hypothesis. Mechanism plus a well-defined indication with a validated endpoint, plus direct human evidence that the target matters there, plus an accessible target, is a different proposition — and it is the one that produces drugs.

The ratings, verbatim

Note the two ❌ ratings are ❌ for opposite reasons. The NPY rating means the trial has not been run and there is no way to run it yet. The NK1 rating means the trials were run, repeatedly, by well-resourced groups, and failed — evidence present and negative, which is a stronger epistemic position than most ❌ ratings in this book. Respond to them differently: the first invites a study, the second records a settled result.

The dossier field

Field 3 — Across the blood-brain barrier. For any CNS peptide claim: is the site of action central; what is the proposed route in; what human evidence supports that route; would peripheral action suffice; is the therapy a peptide, or is the peptide merely the target; and what is your plausibility verdict before consulting efficacy data.

An unaddressed delivery question in a claim about brain function is not a gap in your research. It is a finding about the claim.

Carry forward

• To Chapter 27: a peptide can be a delivery address rather than a medicine.
• To Chapter 28: a small molecule can raise the body's own peptides by blocking their degradation.
• To Chapter 30: the barrier logic that excludes peptides from the brain is the same physical logic that limits what a topical peptide can do.
• To everything: what was actually tested in humans, and what did it show?